banda transcan 2 2016ul

Title: High resolution project on prognosis and CARE of cancer patients.


Project Coordinator:
Milena SANT (Italy) Fondazione IRCCS Istituto Nazionale dei Tumori, Milan


Project Partners:
Karin M. G. HAUSTERMANS (Belgium) University Hospitals Leuven, Leuven
Pascale GROSCLAUDE (France ) Francim: Réseau Français des registres de cancer, Toulouse
Alexander KATALINIC (Germany) Institute for Cancer Epidemiology e.V., University Lübeck Cancer Registry of Schleswig-Holstein, Lübeck
Magdalena BIELSKA-LASOTA (Poland) National Institute of Public Health ñ National Institute of Hygiene (NIPHñNIH), Warszawa
Maja PRIMIC ZAKELI (Slovenia) Institute of Oncology Ljubljana, Ljubljana
Maria-José SANCHEZ-PEREZ (Spain) Granada Cancer Registry, Escuela Andaluza de Salùd Publica. CIBERESP. Instituto de Investigacion Biosanitaria. Granada


Project Abstract:
Cancer survival inequalities documented by EUROCARE need to be explained by Population Based Cancer Registry (CR) High Resolution (HR) studies that capture innovation in cancer diagnosis and treatment and investigate whether co-morbidities influence outcome and treatments. Main Aim: Study influence of patterns of care and co-morbidities on clinical outcomes in breast (BC) and colorectal cancer (CC) patients diagnosed in 2011-14 in some EU areas. Specific aims: Investigate influence of co-morbidity on treatment choice, adhesion to clinical guidelines, relapse and disease-free survival and their association with BC and CC prognostic characteristics. Additional aim: CRs possibility to access biobanks in their areas will be piloted through the validation of a plasma derived microRNA signature. Design &Work Plan. Each CR will recruit a sample of 500 cases per tumour site, and will abstract information on stage, diagnostic exams, morphology and bio-molecular subtype, treatment, co-morbidity and follow-up, from clinical records (as with HR study protocol). Data will be centralized and multivariable survival analyses will be carried out. In addition, a plasma-based microRNA signature predictive of distant metastatization in early stage BC will be validated using biobanks in partners areas. The project will be coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori and organised in 4 WPs. The research consortium includes CRs with past experience in HR studies, 1 basic research and 2 clinical teams, epidemiologists, public health experts.

Final Summary:
Cancer survival inequalities documented by EUROCARE need to be explained by Population Based Cancer Registry (CR) High Resolution (HR) studies which capture innovation in cancer diagnosis and treatment, and investigate whether co-morbidities influence outcome and treatments.

The main aim of the project was to study the influence of patterns of care and co-morbidities on clinical outcomes in breast (BC) and colorectal cancer (CC) patients diagnosed in 2011-14 in a number of EU areas.

Aims: (i) the influence of co-morbidity on treatment choice, adhesion to clinical guidelines, relapse and disease-free survival and their association with BC and CC prognostic characteristics; (ii) the CRs possibility to access biobanks in their areas, piloted through the validation of a plasma derived microRNA signature. Each CR recruited a sample of 500 breast and/or colorectal cancer cases, and abstracted information on stage, diagnostic exams, morphology and bio-molecular subtype, treatment, co-morbidity and follow-up, from clinical records (as with HR study protocol). Data was centralized and multivariable survival analyses were carried out. In addition, a plasma-based microRNA signature predictive of distant metastatisation in early stage BC were validated using biobanks in partners areas. The project was coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori and organised in 4 WPs. The research consortium includes CRs with past experience in HR studies, 1 basic research and 2 clinical teams, epidemiologists, and public health experts.

 

(Project funded under JTC 2013)


TRANSCAN News

 TRANSCAN-3 news on:
twitter logoinkedin social media logo

TRANSCAN-3   JOINT TRANSNATIONAL CALL 2022 on:
 "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"  

is open for submission

Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl


Other news:

The Digital Institute for Cancer Outcomes Research (DIGICORE),  is delighted to announce an innovative new training programme for early career researchers in oncology: IDEAL4RWE.
 Please register for an introductory webinar on the19th April 2022(https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk


 The first TRANSCAN-3 call (JTC 2021) on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
is closed for submission

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

Newsletters

The TRANSCAN-3 newsletters are published at: https://www.transcan.eu/

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter


All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 10 guests and no members online